Matricelf

Matricelf is a preclinical-stage biotechnology company focused on personalized regenerative medicine. The company develops proprietary autologous 3D tissue engineering platforms that create functional, patient-specific neural implants. Their manufacturing process utilizes a patient’s own blood-derived induced pluripotent stem cells (iPSCs) and an extracellular matrix hydrogel created from a sample of the patient's omentum. By differentiating these stem cells within the autologous hydrogel, the company generates functional neural tissue engineered to bridge damaged spinal tissue, with the goal of restoring lost function while minimizing the risk of rejection.

The company’s lead program addresses spinal cord injury, a condition with high unmet medical needs and significant economic burden. Preclinical studies using FDA-accepted animal models have demonstrated functional recovery, providing a foundation for clinical translation. Matricelf is currently advancing its clinical program, including an agreement with Sheba Medical Center for clinical manufacturing, as it works toward a planned first-in-human clinical trial. Beyond spinal cord injury, the company’s regenerative platform is being researched for potential applications in treating stroke, traumatic brain injury, and other cardiovascular and retinal conditions.